Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 472

1.

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.

Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Mahle L, Grindedal EMM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Jensen TD, Osther PJS, Helfand BT, Genova E, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Lam J, Taylor L, Salinas M, Feliubadaló L, Oosterwijk JC, van Zelst-Stams W, Cook J, Rosario DJ, Domchek S, Powers J, Buys S, O'Toole K, Ausems MGEM, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, Aprikian A, van Randeraad H, Davidson R, Longmuir M, Ruijs MWG, Helderman van den Enden ATJM, Adank M, Williams R, Andrews L, Murphy DG, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Morton C, Shackleton K, Snape K, Hanson H, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Ramon Y Cajal T, Zgajnar J, Brewer C, Gadea N, Brady AF, van Os T, Gallagher D, Johannsson O, Donaldson A, Barwell J, Nicolai N, Friedman E, Obeid E, Greenhalgh L, Murthy V, Copakova L, Saya S, McGrath J, Cooke P, Rønlund K, Richardson K, Henderson A, Teo SH, Arun B, Kast K, Dias A, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Eccles DM, Tricker K, Eyfjord J, Falconer A, Foster C, Gronberg H, Hamdy FC, Stefansdottir V, Khoo V, Lindeman GJ, Lubinski J, Axcrona K, Mikropoulos C, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Dudderidge T; IMPACT Study Collaborators, Offman J, Kote-Jarai Z, Vickers A, Lilja H, Eeles RA.

Eur Urol. 2019 Sep 12. pii: S0302-2838(19)30668-2. doi: 10.1016/j.eururo.2019.08.019. [Epub ahead of print]

PMID:
31537406
2.

Editorial Comment.

Kapoor J, Koschel S, Murphy DG.

J Urol. 2019 Sep 16:10109701JU0000582676488818f. doi: 10.1097/01.JU.0000582676.48881.8f. [Epub ahead of print] No abstract available.

PMID:
31524573
3.

NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy.

Hardcastle N, Hofman MS, Lee CY, Callahan J, Selbie L, Foroudi F, Shaw M, Chander S, Lim A, Chesson B, Murphy DG, Kron T, Siva S.

Radiat Oncol. 2019 Sep 5;14(1):164. doi: 10.1186/s13014-019-1359-0.

4.

Re: A Comparative Study of Robot-assisted and Open Radical Prostatectomy in 10 790 Men Treated by Highly Trained Surgeons for Both Procedures.

Teh J, Koschel S, Thangasamy I, Sathianathen N, Murphy DG, Eapen R.

Eur Urol. 2019 Aug 30. pii: S0302-2838(19)30677-3. doi: 10.1016/j.eururo.2019.08.027. [Epub ahead of print] No abstract available.

PMID:
31477345
5.

TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol.

Martin J, Keall P, Siva S, Greer P, Christie D, Moore K, Dowling J, Pryor D, Chong P, McLeod N, Raman A, Lynam J, Smart J, Oldmeadow C, Tang CI, Murphy DG, Millar J, Tai KH, Holloway L, Reeves P, Hayden A, Lim T, Holt T, Sidhom M.

BMJ Open. 2019 Aug 20;9(8):e030731. doi: 10.1136/bmjopen-2019-030731.

6.

Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy.

Thang SP, Violet J, Sandhu S, Iravani A, Akhurst T, Kong G, Ravi Kumar A, Murphy DG, Williams SG, Hicks RJ, Hofman MS.

Eur Urol Oncol. 2018 Dec 13. pii: S2588-9311(18)30205-0. doi: 10.1016/j.euo.2018.11.007. [Epub ahead of print]

PMID:
31412006
7.

A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.

Sathianathen NJ, Alarid-Escudero F, Kuntz KM, Lawrentschuk N, Bolton DM, Murphy DG, Kim SP, Konety BR.

Eur Urol Oncol. 2019 Jan 30. pii: S2588-9311(19)30005-7. doi: 10.1016/j.euo.2019.01.004. [Epub ahead of print]

PMID:
31411985
8.

Report of the third Asian Prostate Cancer study meeting.

Lojanapiwat B, Lee JY, Gang Z, Kim CS, Fai NC, Hakim L, Umbas R, Ong TA, Lim J, Letran JL, Chiong E, Lee SH, Türkeri L, Murphy DG, Moretti K, Cooperberg M, Carlile R, Hinotsu S, Hirao Y, Kitamura T, Horie S, Onozawa M, Kitagawa Y, Namiki M, Fukagai T, Miyazaki J, Akaza H.

Prostate Int. 2019 Jun;7(2):60-67. doi: 10.1016/j.prnil.2018.06.001. Epub 2018 Jun 14.

9.

Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer.

Butcher G, Howard H, Sathianathen N, Catto JWF, Murphy DG.

Eur Urol. 2019 Jul 25. pii: S0302-2838(19)30542-1. doi: 10.1016/j.eururo.2019.07.018. [Epub ahead of print] No abstract available.

PMID:
31352977
10.

Re: PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients with Metastatic Castration-resistant Prostate Cancer.

McLennan D, Sathianathen N, Alghazo O, Azad A, Murphy DG.

Eur Urol. 2019 Jul 25. pii: S0302-2838(19)30550-0. doi: 10.1016/j.eururo.2019.07.026. [Epub ahead of print] No abstract available.

PMID:
31352976
11.

Characterizing high-grade serous papillary carcinoma of tunica vaginalis.

Qu LG, Teh J, Mitchell C, Gyorki DE, Hicks RJ, Murphy DG.

Urol Case Rep. 2019 Jun 21;26:100949. doi: 10.1016/j.eucr.2019.100949. eCollection 2019 Sep.

12.

Are we ready to adopt the European Association of Urology recommendations on multiparametric magnetic resonance imaging in the early detection of prostate cancer?

Thangasamy IA, Alghazo O, Murphy DG.

Investig Clin Urol. 2019 Jul;60(4):225-226. doi: 10.4111/icu.2019.60.4.225. Epub 2019 May 29. No abstract available.

13.

Detection and localisation of primary prostate cancer using 68 Ga-PSMA PET/CT compared with mpMRI and radical prostatectomy specimens.

Kalapara AA, Nzenza T, Pan HY, Ballok Z, Ramdave S, O'Sullivan R, Ryan A, Cherk M, Hofman MS, Konety BR, Lawrentschuk N, Bolton D, Murphy DG, Grummet JP, Frydenberg M.

BJU Int. 2019 Jul 1. doi: 10.1111/bju.14858. [Epub ahead of print]

PMID:
31260602
14.

The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD).

Pretzsch CM, Voinescu B, Mendez MA, Wichers R, Ajram L, Ivin G, Heasman M, Williams S, Murphy DG, Daly E, McAlonan GM.

J Psychopharmacol. 2019 Jun 25:269881119858306. doi: 10.1177/0269881119858306. [Epub ahead of print]

PMID:
31237191
15.

Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer.

Porter LH, Lawrence MG, Wang H, Clark AK, Bakshi A, Obinata D, Goode D, Papargiris M, Mural, Clouston D, Ryan A, Norden S, Corey E, Nelson PS, Isaacs JT, Grummet J, Kourambas J, Sandhu S, Murphy DG, Pook D, Frydenberg M, Taylor RA, Risbridger GP.

Prostate. 2019 Aug;79(11):1326-1337. doi: 10.1002/pros.23839. Epub 2019 Jun 18.

PMID:
31212368
16.

The role of 18F-FDG-PET/CT in evaluating retroperitoneal masses -Keeping your eye on the ball!

Hung TJ, McLean L, Mitchell C, Pascoe C, Lawrentschuk N, Murphy DG, Iravani A, Singh D, Hofman MS, Zidan L, Akhurst T, Lewin J, Hicks RJ.

Cancer Imaging. 2019 May 29;19(1):28. doi: 10.1186/s40644-019-0217-5.

17.

Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team.

Murphy DG, Hofman MS, Azad A, Violet J, Hicks RJ, Lawrentschuk N.

BJU Int. 2019 May 24. doi: 10.1111/bju.14814. [Epub ahead of print] No abstract available.

PMID:
31127664
18.

Re: Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer.

Alghazo O, Thangasamy I, Sathianathen N, Murphy DG.

Eur Urol. 2019 Oct;76(4):536-537. doi: 10.1016/j.eururo.2019.04.028. Epub 2019 May 14. No abstract available.

PMID:
31101535
19.

Salvage Radical Prostatectomy of Recurrent Prostate Cancer: Morbidity and Functional Outcomes from a Large Multicenter Series of Open versus Robotic Approaches.

Gontero P, Marra G, Alessio P, Filippini C, Oderda M, Munoz F, Linares E, Sanchez-Salas R, Challacombe B, Dasgupta P, Goonewardene S, Popert R, Cahill D, Gillatt D, Persad R, Palou J, Joniau S, Piechaud T, Morlacco A, Vidit S, Rouprêt M, De La Taille A, Albisinni S, Gandaglia G, Mottrie A, Joshi S, Fiscus G, Berger A, Aron M, Van Der Poel H, Tilki D, Lawrentschuk N, Murphy DG, Leung G, Davis J, Karnes RJ; Collaborators.

J Urol. 2019 May 10:101097JU0000000000000327. doi: 10.1097/JU.0000000000000327. [Epub ahead of print]

PMID:
31075058
20.

Large-scale analyses of the relationship between sex, age and intelligence quotient heterogeneity and cortical morphometry in autism spectrum disorder.

Bedford SA, Park MTM, Devenyi GA, Tullo S, Germann J, Patel R, Anagnostou E, Baron-Cohen S, Bullmore ET, Chura LR, Craig MC, Ecker C, Floris DL, Holt RJ, Lenroot R, Lerch JP, Lombardo MV, Murphy DGM, Raznahan A, Ruigrok ANV, Smith E, Spencer MD, Suckling J, Taylor MJ, Thurm A; MRC AIMS Consortium, Lai MC, Chakravarty MM.

Mol Psychiatry. 2019 Apr 26. doi: 10.1038/s41380-019-0420-6. [Epub ahead of print]

PMID:
31028290
21.

Where to Next for Theranostics in Prostate Cancer?

Murphy DG, Sathianathen N, Hofman MS, Azad A, Lawrentschuk N.

Eur Urol Oncol. 2019 Mar;2(2):163-165. doi: 10.1016/j.euo.2019.03.004. Epub 2019 Mar 29. No abstract available.

PMID:
31017092
22.

Adverse impact of malnutrition markers on major abdominopelvic cancer surgery.

Sathianathen NJ, Kwaan M, Lawrentschuk N, Weight CJ, Kim SP, Murphy DG, Moon DA, Konety BR.

ANZ J Surg. 2019 May;89(5):509-514. doi: 10.1111/ans.15129. Epub 2019 Apr 8.

PMID:
30959573
23.

Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Teh J, Narasimhan V, Schultz S, Sathianathen N, Murphy DG.

Eur Urol. 2019 Jul;76(1):126-127. doi: 10.1016/j.eururo.2019.03.002. Epub 2019 Mar 14. No abstract available.

PMID:
30879791
24.

Adding Colour to the Grey Zone of Advanced Prostate Cancer.

Murphy DG, Padhani AR, Ost P.

Eur Urol Focus. 2019 Mar;5(2):123-124. doi: 10.1016/j.euf.2019.02.015. Epub 2019 Feb 26.

PMID:
30824379
25.

The influence of BRCA2 mutation on localized prostate cancer.

Taylor RA, Fraser M, Rebello RJ, Boutros PC, Murphy DG, Bristow RG, Risbridger GP.

Nat Rev Urol. 2019 May;16(5):281-290. doi: 10.1038/s41585-019-0164-8. Review.

PMID:
30808988
26.

Familial risk of autism alters subcortical and cerebellar brain anatomy in infants and predicts the emergence of repetitive behaviors in early childhood.

Pote I, Wang S, Sethna V, Blasi A, Daly E, Kuklisova-Murgasova M, Lloyd-Fox S, Mercure E, Busuulwa P, Stoencheva V, Charman T, Williams SCR, Johnson MH, Murphy DGM, McAlonan GM; BASIS Team.

Autism Res. 2019 Apr;12(4):614-627. doi: 10.1002/aur.2083. Epub 2019 Feb 22.

27.

Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart.

Vapiwala N, Hofman MS, Murphy DG, Williams S, Sweeney C.

J Clin Oncol. 2019 Apr 1;37(10):765-769. doi: 10.1200/JCO.18.01927. Epub 2019 Feb 22. No abstract available.

PMID:
30794477
28.

Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.

Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D, Bolton D, Hofman MS, Lawrentschuk N, Murphy DG.

Eur Urol. 2019 Feb 14. pii: S0302-2838(19)30095-8. doi: 10.1016/j.eururo.2019.01.049. [Epub ahead of print] Review.

PMID:
30773328
29.

Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder.

Pretzsch CM, Freyberg J, Voinescu B, Lythgoe D, Horder J, Mendez MA, Wichers R, Ajram L, Ivin G, Heasman M, Edden RAE, Williams S, Murphy DGM, Daly E, McAlonan GM.

Neuropsychopharmacology. 2019 Jul;44(8):1398-1405. doi: 10.1038/s41386-019-0333-8. Epub 2019 Feb 6.

PMID:
30758329
30.

Investigating the factors underlying adaptive functioning in autism in the EU-AIMS Longitudinal European Autism Project.

Tillmann J, San José Cáceres A, Chatham CH, Crawley D, Holt R, Oakley B, Banaschewski T, Baron-Cohen S, Bölte S, Buitelaar JK, Durston S, Ham L, Loth E, Simonoff E, Spooren W, Murphy DG, Charman T; EU-AIMS LEAP group.

Autism Res. 2019 Apr;12(4):645-657. doi: 10.1002/aur.2081. Epub 2019 Feb 11.

31.

Altered Connectivity Between Cerebellum, Visual, and Sensory-Motor Networks in Autism Spectrum Disorder: Results from the EU-AIMS Longitudinal European Autism Project.

Oldehinkel M, Mennes M, Marquand A, Charman T, Tillmann J, Ecker C, Dell'Acqua F, Brandeis D, Banaschewski T, Baumeister S, Moessnang C, Baron-Cohen S, Holt R, Bölte S, Durston S, Kundu P, Lombardo MV, Spooren W, Loth E, Murphy DGM, Beckmann CF, Buitelaar JK; EU-AIMS LEAP group.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2019 Mar;4(3):260-270. doi: 10.1016/j.bpsc.2018.11.010. Epub 2018 Dec 5.

PMID:
30711508
32.

Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics.

Murphy DG, Azad AA, Sandhu S, Violet J, Hofman MS.

Eur Urol. 2019 Jun;75(6):927-928. doi: 10.1016/j.eururo.2018.12.039. Epub 2019 Jan 5. No abstract available.

PMID:
30616952
33.

Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.

Matta R, Chapple CR, Fisch M, Heidenreich A, Herschorn S, Kodama RT, Koontz BF, Murphy DG, Nguyen PL, Nam RK.

Eur Urol. 2019 Mar;75(3):464-476. doi: 10.1016/j.eururo.2018.12.003. Epub 2018 Dec 17.

PMID:
30573316
34.

Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework.

Reynolds HM, Williams S, Jackson P, Mitchell C, Hofman MS, Hicks RJ, Murphy DG, Haworth A.

BJU Int. 2019 Jun;123(6):1020-1030. doi: 10.1111/bju.14648. Epub 2019 Jan 28.

PMID:
30536698
35.

Highly Diverse Hepatitis C Strains Detected in Sub-Saharan Africa Have Unknown Susceptibility to Direct-Acting Antiviral Treatments.

Davis C, Mgomella GS, da Silva Filipe A, Frost EH, Giroux G, Hughes J, Hogan C, Kaleebu P, Asiki G, McLauchlan J, Niebel M, Ocama P, Pomila C, Pybus OG, Pépin J, Simmonds P, Singer JB, Sreenu VB, Wekesa C, Young EH, Murphy DG, Sandhu M, Thomson EC.

Hepatology. 2019 Apr;69(4):1426-1441. doi: 10.1002/hep.30342. Epub 2019 Mar 22.

36.

PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics.

Eapen RS, Nzenza TC, Murphy DG, Hofman MS, Cooperberg M, Lawrentschuk N.

World J Urol. 2019 Jul;37(7):1255-1261. doi: 10.1007/s00345-018-2524-z. Epub 2018 Oct 29.

PMID:
30374609
37.

GABAA receptor availability is not altered in adults with autism spectrum disorder or in mouse models.

Horder J, Andersson M, Mendez MA, Singh N, Tangen Ä, Lundberg J, Gee A, Halldin C, Veronese M, Bölte S, Farde L, Sementa T, Cash D, Higgins K, Spain D, Turkheimer F, Mick I, Selvaraj S, Nutt DJ, Lingford-Hughes A, Howes OD, Murphy DG, Borg J.

Sci Transl Med. 2018 Oct 3;10(461). pii: eaam8434. doi: 10.1126/scitranslmed.aam8434.

38.

The Neuroanatomy of Autism Spectrum Disorder Symptomatology in 22q11.2 Deletion Syndrome.

Gudbrandsen M, Daly E, Murphy CM, Wichers RH, Stoencheva V, Perry E, Andrews D, Blackmore CE, Rogdaki M, Kushan L, Bearden CE, Murphy DGM, Craig MC, Ecker C.

Cereb Cortex. 2018 Oct 1. doi: 10.1093/cercor/bhy239. [Epub ahead of print]

PMID:
30272146
39.

Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.

Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J, Tai KH, Udovicich C, Lim A, Selbie L, Hofman MS, Kron T, Moon D, Goad J, Lawrentschuk N, Foroudi F.

Eur Urol. 2018 Oct;74(4):455-462. doi: 10.1016/j.eururo.2018.06.004. Epub 2018 Jun 29.

PMID:
30227924
40.

Editorial Comment.

van den Bergh RCN, van der Poel HG, Murphy DG.

J Urol. 2018 Dec;200(6):1254-1255. doi: 10.1016/j.juro.2018.06.094. Epub 2018 Sep 5. No abstract available.

PMID:
30193091
41.

Less, not More, Antibiotics Please.

Murphy DG, Alghazo O, Pascoe C, Lawrentschuk N.

Eur Urol Focus. 2018 Aug 31. pii: S2405-4569(18)30230-X. doi: 10.1016/j.euf.2018.08.011. [Epub ahead of print] No abstract available.

PMID:
30177401
42.

Current management of radiation cystitis: a review and practical guide to clinical management.

Pascoe C, Duncan C, Lamb BW, Davis NF, Lynch TH, Murphy DG, Lawrentschuk N.

BJU Int. 2019 Apr;123(4):585-594. doi: 10.1111/bju.14516. Epub 2018 Nov 28. Review.

PMID:
30113758
43.

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.

Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, Lister N, Pook D, Pezaro CJ, Goode DL, Rebello RJ, Clark AK, Papargiris M, Van Gramberg J, Hanson AR, Banks P, Wang H, Niranjan B, Keerthikumar S, Hedwards S, Huglo A, Yang R, Henzler C, Li Y, Lopez-Campos F, Castro E, Toivanen R, Azad A, Bolton D, Goad J, Grummet J, Harewood L, Kourambas J, Lawrentschuk N, Moon D, Murphy DG, Sengupta S, Snow R, Thorne H, Mitchell C, Pedersen J, Clouston D, Norden S, Ryan A, Dehm SM, Tilley WD, Pearson RB, Hannan RD, Frydenberg M, Furic L, Taylor RA, Risbridger GP.

Eur Urol. 2018 Nov;74(5):562-572. doi: 10.1016/j.eururo.2018.06.020. Epub 2018 Jul 23.

PMID:
30049486
44.

Patterns of care and outcomes for men diagnosed with prostate cancer in Victoria: an update.

Wang LL, Begashaw K, Evans M, Earnest A, Evans SM, Millar JL, Murphy DG, Moon D.

ANZ J Surg. 2018 Oct;88(10):1037-1042. doi: 10.1111/ans.14722. Epub 2018 Jul 25.

PMID:
30047208
45.

Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging.

Hofman MS, Iravani A, Nzenza T, Murphy DG.

Urol Clin North Am. 2018 Aug;45(3):503-524. doi: 10.1016/j.ucl.2018.03.016. Epub 2018 Jun 15. Review.

PMID:
30031469
46.

Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017.

Chiong E, Murphy DG, Akaza H, Buchan NC, Chung BH, Kanesvaran R, Khochikar M, Letran J, Lojanapiwat B, Ng CF, Ong T, Pu YS, Saad M, Schubach K, Türkeri L, Umbas R, Le Chuyen V, Williams S, Ye DW; ANZUP Cancer Trials Group, Davis ID.

BJU Int. 2019 Jan;123(1):22-34. doi: 10.1111/bju.14489. Epub 2018 Aug 19. Review.

PMID:
30019467
47.

Getting the Balance Right-The Benefits and Uncertainties of Focal Therapy for Significant Prostate Cancer.

Murphy DG, Tilki D.

Eur Urol. 2018 Oct;74(4):430-431. doi: 10.1016/j.eururo.2018.06.035. Epub 2018 Jul 13. No abstract available.

PMID:
30007818
48.

Sex-chromosome dosage effects on gene expression in humans.

Raznahan A, Parikshak NN, Chandran V, Blumenthal JD, Clasen LS, Alexander-Bloch AF, Zinn AR, Wangsa D, Wise J, Murphy DGM, Bolton PF, Ried T, Ross J, Giedd JN, Geschwind DH.

Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):7398-7403. doi: 10.1073/pnas.1802889115. Epub 2018 Jun 26.

49.

PRECISION delivers on the PROMIS of mpMRI in early detection.

Nzenza T, Murphy DG.

Nat Rev Urol. 2018 Sep;15(9):529-530. doi: 10.1038/s41585-018-0046-5. No abstract available.

PMID:
29930321
50.

Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis.

Sathianathen NJ, Kuntz KM, Alarid-Escudero F, Lawrentschuk NL, Bolton DM, Murphy DG, Weight CJ, Konety BR.

J Urol. 2018 Dec;200(6):1215-1220. doi: 10.1016/j.juro.2018.06.016. Epub 2018 Jun 12.

PMID:
29906434

Supplemental Content

Loading ...
Support Center